Skip to main content
. 2015 Nov 28;7(2):1675–1686. doi: 10.18632/oncotarget.6423

Figure 3. Treatment with e8-siRNA#1 inhibits tumor growth in vivo.

Figure 3

Patient derived CSC1 cells stably transfected with a luciferase reporter vector were inoculated into athymic mice. Twice a week mice were intratumorally treated with e8-siRNA (n = 6). A scrambled version of e8-siRNA (Scr-siRNA) was used as control (n = 6). (A) Tumor volume in nude mice treated with e8-siRNA or with Scr-siRNA. Xenograft growth was monitored and showed as mean ± S.D. *p < 0.01. (B) Bioluminescence imaging of three representative mice for each group at 0 and 13 days of treatment. Luciferase imaging of mice whole body was performed twice a week. (C) Comparison of tumors explanted from Scr-siRNA and e8-siRNA#1 treated mice fifteen days after the first treatment. Three representative tumors for each group are shown.